Clinical trials
Phase 4 Diabetes Mellitus, Type 2 trials in Pakistan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 2 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Getz Pharma | 6 |
| Bahria University | 3 |
| GlaxoSmithKline | 3 |
| Dow University of Health Sciences | 1 |
| Dr. Zarmina Younes | 1 |
| Pfizer | 1 |
| Rehman Medical Institute - RMI | 1 |
| SINA Health Education and Welfare Trust | 1 |
| Sanofi | 1 |
| Services Institute of Medical Sciences, Pakistan | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 20 |
| Insulin Resistance | 2 |
| Diabetic Nephropathies | 1 |
| Drug-Related Side Effects and Adverse Reactions | 1 |
| Dyslipidemias | 1 |
| Glucose Metabolism Disorders | 1 |
| Hepatitis C, Chronic | 1 |
| Hypercholesterolemia | 1 |
| Hyperglycemia | 1 |
| Hyperlipoproteinemia Type II | 1 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.